Clinical Trial Update: Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of docetaxel and samarium for hormone-refractory advanced prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Samarium-153 (samarium-153)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED